[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dietary-modification\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dietary-modification":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100210443",false,"NCT02016430","Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)","GRADY","Inclusion Criteria:\n\nCohort 1 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Elevated TMAO metabolizers (\\>5 µM) based on screening test and\u002For eGFR \\\u003C 60 at most recent measurement.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol, which includes a 12-week dietary modification.\n\nCohort 2 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol.\n* eGFR values ranging from 16-59\n\nCohort 3 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol.\n\nExclusion Criteria (all cohorts):\n\n* Significant chronic illness or end-organ dysfunction, including known history of uncompensated heart failure, renal failure, pulmonary disease, hematologic diseases.\n* Active infection or received antibiotics within 2 months of study enrollment\n* Use of over-the-counter probiotic within past month, or ingestion of yogurt within past 7 days\n* Having undergone bariatric procedures or surgeries such as gastric banding or bypass.\n* Pregnancy.\n* Any condition which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial",true,"ALL","18 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23],"NA","Our group has recently identified the association between gut-flora-mediated carnitine and phosphatidylcholine metabolism, specifically trimethylamine-N-oxide (TMAO), and cardiovascular risk. This study investigates the ability for dietary intervention to modulate TMAO levels.",[26,27],"Dietary Modification","Cardiovascular Risk Factor",[29,30,31,32,33],"TMAO","Gut Flora","Dietary Intervention","Choline","Carnitine","RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2014-04-04",{"date":42,"type":20},"2026-12",{"name":44,"class":45},"The Cleveland Clinic","OTHER",1,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100561487","NCT06590805","Electroacupoint for Diminutive Milk Production","Ameliorative Potential of Electroacupoint for Diminutive Milk Production in Lactating Woman","Inclusion Criteria:\n\n* They were complaining of insufficiency of lactation within the first month after cesarean section.\n* They are using mixed feeding; both breast and bottle feeding, between three and six bottles per day.\n* Their age ranged from 25-30 years old.\n* Their body mass index didn't exceeded 30 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Postpartum haemorrhage.\n* Cardiorespiratory disease.\n* Diabetes mellitus.\n* Breast cancer.\n* Previous surgeries in the chest, breast, or the surrounding area.\n* Anemia.\n* Any causes that hindered their normal breastfeeding (retraced, cracked, inflamed, or inverted nipples).\n* Receiving contraceptive pills.\n* Having infants with conditions that may affect the lactation process such as congenital abnormalities of the mouth (tongue tie, cleft palate).\n* Congenital heart disease.","FEMALE","25 Years","30 Years",{"count":57,"type":20},36,[23],"The purpose of this study was to reveal the effect of electroacupoint on scanty milk production in lactating women.",[61,62,26],"Physical Therapy","Electrotherapy",[64,65,66,67],"Electroacupoint","Postnatal care","Diminutive milk production","Lactating woman","2024-09-06",{"date":70,"type":38},"2024-09-19",{"date":72,"type":38},"2024-09-01",{"date":74,"type":20},"2025-06-01",{"name":76,"class":45},"Haytham Ibrahim Morsi",""]